PHP
OVID icon

Parkman Healthcare Partners’s Ovid Therapeutics OVID Stock Holding History

Parkman Healthcare Partners’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$462K Buy
208,205
+7,169
+4% +$12.8K 0.05% 88
2025
Q4 		$328K Sell
201,036
-1,942
-1% -$2.99K 0.03% 100
2025
Q3 		$264K Buy
+202,978
New +$176K 0.03% 91

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Parkman Healthcare Partners's OVID Position: Q1 2026 in Review

Parkman Healthcare Partners increased its Ovid Therapeutics (OVID) stake by 3.6% in Q1 2026, buying an estimated $12.8K and bringing the position to 208,205 shares worth $462K. The position accounts for 0.05% of the portfolio, ranked #88.

Parkman Healthcare Partners first reported a position in OVID in Q3 2025 and has held it in 3 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Parkman Healthcare Partners held 208,205 shares of Ovid Therapeutics worth $462K as of Q1 2026.
  • Parkman Healthcare Partners bought 7,169 Ovid Therapeutics shares in Q1 2026, an estimated $12.8K.
  • Ovid Therapeutics made up 0.05% of Parkman Healthcare Partners's portfolio in Q1 2026, its #88 holding.
  • Parkman Healthcare Partners first reported a position in Ovid Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.